Lentiviral Vectors and Cystic Fibrosis Gene Therapy

Cystic fibrosis (CF) is a chronic autosomic recessive syndrome, caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene, a chloride channel expressed on the apical side of the airway epithelial cells. The lack of CFTR activity brings a dysregulated exchange of ions and water th...

Full description

Bibliographic Details
Main Authors: Castellani, Stefano, Conese, Massimo
Format: Online
Language:English
Published: Molecular Diversity Preservation International (MDPI) 2010
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185599/
id pubmed-3185599
recordtype oai_dc
spelling pubmed-31855992011-10-12 Lentiviral Vectors and Cystic Fibrosis Gene Therapy Castellani, Stefano Conese, Massimo Review Cystic fibrosis (CF) is a chronic autosomic recessive syndrome, caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene, a chloride channel expressed on the apical side of the airway epithelial cells. The lack of CFTR activity brings a dysregulated exchange of ions and water through the airway epithelium, one of the main aspects of CF lung disease pathophysiology. Lentiviral (LV) vectors, of the Retroviridae family, show interesting properties for CF gene therapy, since they integrate into the host genome and allow long-lasting gene expression. Proof-of-principle that LV vectors can transduce the airway epithelium and correct the basic electrophysiological defect in CF mice has been given. Initial data also demonstrate that LV vectors can be repeatedly administered to the lung and do not give rise to a gross inflammatory process, although they can elicit a T cell-mediated response to the transgene. Future studies will clarify the efficacy and safety profile of LV vectors in new complex animal models with CF, such as ferrets and pigs. Molecular Diversity Preservation International (MDPI) 2010-01-29 /pmc/articles/PMC3185599/ /pubmed/21994643 http://dx.doi.org/10.3390/v2020395 Text en © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Castellani, Stefano
Conese, Massimo
spellingShingle Castellani, Stefano
Conese, Massimo
Lentiviral Vectors and Cystic Fibrosis Gene Therapy
author_facet Castellani, Stefano
Conese, Massimo
author_sort Castellani, Stefano
title Lentiviral Vectors and Cystic Fibrosis Gene Therapy
title_short Lentiviral Vectors and Cystic Fibrosis Gene Therapy
title_full Lentiviral Vectors and Cystic Fibrosis Gene Therapy
title_fullStr Lentiviral Vectors and Cystic Fibrosis Gene Therapy
title_full_unstemmed Lentiviral Vectors and Cystic Fibrosis Gene Therapy
title_sort lentiviral vectors and cystic fibrosis gene therapy
description Cystic fibrosis (CF) is a chronic autosomic recessive syndrome, caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene, a chloride channel expressed on the apical side of the airway epithelial cells. The lack of CFTR activity brings a dysregulated exchange of ions and water through the airway epithelium, one of the main aspects of CF lung disease pathophysiology. Lentiviral (LV) vectors, of the Retroviridae family, show interesting properties for CF gene therapy, since they integrate into the host genome and allow long-lasting gene expression. Proof-of-principle that LV vectors can transduce the airway epithelium and correct the basic electrophysiological defect in CF mice has been given. Initial data also demonstrate that LV vectors can be repeatedly administered to the lung and do not give rise to a gross inflammatory process, although they can elicit a T cell-mediated response to the transgene. Future studies will clarify the efficacy and safety profile of LV vectors in new complex animal models with CF, such as ferrets and pigs.
publisher Molecular Diversity Preservation International (MDPI)
publishDate 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185599/
_version_ 1611479070529290240